K. Kelly

K. Kelly, Chin-Shang Li, M. Daly, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Title Increasing Rates of No Treatment in Advanced-Stage Non – Small Cell Lung Cancer Patients : A Propensity-Matched Analysis Permalink

K. Kelly, Chin-Shang Li, M. Daly, 2022 .

International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials

G. Scagliotti, H. Wakelee, F. Hirsch, 2022, Journal of Thoracic Oncology.

Management of a superior sulcus (pancoast) tumor.

K. Kelly, B. Solomon, 2005, Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016, Journal for ImmunoTherapy of Cancer.

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma

I. Wistuba, K. Kelly, D. Gandara, 2017 .

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)

I. Wistuba, K. Kelly, D. Gandara, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and gefitinib/placebo maintenance in patients with inoperable stage III non-small cell lung cancer

K. Kelly, D. Gandara, L. Gaspar, 2005 .

Small Cell Lung Cancer, Version 2.2022

P. Iyengar, B. Loo, A. Chiang, 2021 .

Chemotherapy for Small Cell Lung Cancer 58

K. Kelly, F. Shepherd, C. Huang, 2018 .

Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.

R. Govindan, D. Carbone, P. Fidias, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.

R. Govindan, R. Herbst, K. Kelly, 2006, Lung cancer.

Potential Role of Platelet-Derived Growth Factor Receptor Inhibition Using Imatinib in Combination with Docetaxel in the Treatment of Recurrent Non-small Cell Lung Cancer

M. Mayo, K. Kelly, O. Tawfik, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer

K. Kelly, D. Proia, W. Murphy, 2015, Oncoimmunology.

Updated analysis of SWOG 0023: A randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer

J. Jett, K. Kelly, D. Gandara, 2007 .

Single-Institution Experience with Pemetrexedand Bevacizumab as Salvage Therapy in AdvancedNon–Small-Cell Lung Cancer

K. Kelly, P. Bunn, G. Weiss, 2007 .

A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer.

K. Kelly, P. Bunn, S. Prindiville, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome.

K. Kelly, John D. Mitchell, W. Franklin, 2007, The Lancet. Oncology.

Treatment of Thymoma: A Comparative Study Between Thailand and the United States and a Review of the Literature

P. Sunpaweravong, K. Kelly, 2004, American journal of clinical oncology.

Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.

N. Hanna, K. Kelly, P. Bunn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Role of Targeted Agents in Adjuvant Therapy for Non–Small Cell Lung Cancer

K. Kelly, 2005, Clinical Cancer Research.

Gefitinib: phase II and III results in advanced non-small cell lung cancer.

K. Kelly, S. Averbuch, 2004, Seminars in oncology.

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

R. Herbst, K. Kelly, D. Gandara, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

On the design, conduct and lessons learned from Lung-MAP (SWOGS1400): A biomarker-driven master protocol to evaluate biomarker-driventherapies for previously-treated squamous lung cancer

Stacey, L. Schwartz, M. Leblanc, 2021 .

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)

L. Schwartz, R. Herbst, F. Hirsch, 2021, Journal for ImmunoTherapy of Cancer.

Brief Report: SWOG S1400B (), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

R. Herbst, K. Kelly, D. Gandara, 2020 .

Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).

R. Herbst, J. Bradley, K. Kelly, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Ever-Increasing Number of Trial Eligibility Criteria: Time to Bend the Curve.

J. Bradley, K. Kelly, T. Stinchcombe, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Current Treatment Paradigms for Locally Advanced Non-small Cell Lung Cancer

K. Kelly, J. Rigas, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Peptide amidating activity in human bronchoalveolar lavage fluid.

M. Tockman, J. Mulshine, K. Kelly, 1996, Lung cancer.

Detection of K-ras oncogene mutations by polymerase chain reaction-based ligase chain reaction.

J. Mulshine, K. Kelly, R. Modali, 1996, Analytical Biochemistry.

Prospective trial evaluating immunocytochemical‐based sputum techniques for early lung cancer detection: Assays for promotion factors in the bronchial lavage

M. Tockman, S. Piantadosi, J. Mulshine, 1993, Journal of cellular biochemistry. Supplement.

Clinical Trials Integrating Immunotherapy and Radiation for Non–Small-Cell Lung Cancer

K. Kelly, M. Daly, A. Monjazeb, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Quality of life in advanced non-small-cell lung cancer: Results of a Southwest Oncology Group randomized trial

J. Crowley, K. Kelly, P. Grevstad, 2002, Quality of Life Research.

Title DISEASE CONTROL RATE AT 8 WEEKS PREDICTS SUBSEQUENT SURVIVAL IN PLATINUM-TREATED EXTENSIVE STAGE SMALL CELL LUNG CANCER ( ES-SCLC ) : A PATIENT LEVEL ANALYSIS OF SWOG TRIALS Permalink

K. Kelly, D. Gandara, J. Moon, 2015 .

Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer

K. Kelly, C. Huang, P. Neupane, 2016, Front. Oncol..

Metabolomic Markers of Altered Nucleotide Metabolism in Early Stage Adenocarcinoma

Oliver Fiehn, Kyoungmi Kim, Karen Kelly, 2015, Cancer Prevention Research.

First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.

M. Socinski, R. Herbst, F. Hirsch, 2018 .

MA16.10 Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates

M. Socinski, R. Herbst, F. Hirsch, 2017 .

Medical treatment of lung cancer.

K. Kelly, N. Mikhaeel-Kamel, 1999, Journal of thoracic imaging.

A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G).

L. Schwartz, R. Herbst, F. Hirsch, 2019, Journal of Clinical Oncology.

Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753).

L. Schwartz, R. Herbst, F. Hirsch, 2019, Journal of Clinical Oncology.

A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).

L. Schwartz, R. Herbst, F. Hirsch, 2019, Journal of Clinical Oncology.

A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center study.

K. Kelly, P. Bunn, 1995, Seminars in oncology.

A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): Final report of SWOG 0342

Edward S. Kim, R. Herbst, K. Kelly, 2007 .

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).

I. Wistuba, J. Heymach, K. Kelly, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Preliminary results

K. Kelly, F. Fossella, J. Schiller, 2004 .

Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction

Helen X. Chen, K. Kelly, Lisa I. Wang, 2021, Journal of Experimental & Clinical Cancer Research.

Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.

K. Kelly, G. Weiss, A. Heydebreck, 2016 .

Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses

Kyoungmi Kim, Karen Kelly, L Renee Ruhaak, 2013, Analytical and Bioanalytical Chemistry.

New chemotherapy agents for small cell lung cancer.

K. Kelly, 2000, Chest.

A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer

Edward J. Kim, J. Riess, K. Kelly, 2022, Cancer Chemotherapy and Pharmacology.

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

K. Kelly, J. Infante, N. Iannotti, 2018, Cancer.

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.

K. Kelly, G. Weiss, J. Infante, 2015 .

A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study.

K. Kelly, P. Bunn, 1995, Seminars in oncology.

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.

J. Crowley, K. Kelly, A. Wozniak, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer.

K. Kelly, P. Bunn, 2000, Clinical lung cancer.

A Phase I / II Trial of Paclitaxel , Carboplatin , and Gemcitabine in Untreated Patients with Advanced Non-Small Cell Lung Cancer 1

James D. Murphy, K. Kelly, P. Bunn, 2000 .

A phase 2 clinical trial of pemetrexed plus gemcitabine as front-line chemotherapy for patients with malignant pleural mesothelioma (MPM).

L. Bloss, C. Obasaju, K. Kelly, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of routine chest radiotherapy in small-cell lung cancer. An issue of timing and stage.

K. Kelly, P. Bunn, 1993, Chest.

Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D.

R. Herbst, J. Bradley, K. Kelly, 2017 .

A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B.

R. Herbst, J. Bradley, K. Kelly, 2017 .

A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C.

R. Herbst, K. Kelly, D. Gandara, 2017 .

Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy

G. Scagliotti, H. Wakelee, T. Mok, 2018, Clinical lung cancer.

Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor

K. Kelly, H. Safran, D. Spigel, 2022, Future oncology.

Exposure-response and PD-L1 expression analysis of second-line avelumab in patients with advanced NSCLC: Data from the JAVELIN Solid Tumor trial.

K. Kelly, C. Verschraegen, D. Spigel, 2017 .

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

R. Heist, K. Kelly, E. Vokes, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.

J. Crowley, K. Kelly, P. Bunn, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Journal Pre-proof rThe Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic Driven Non-Small Cell Lung Cancer: A University California Lung Cancer Consortium Retrospective Study

Goldman, S. Schokrpur, K. Kelly, 2022 .

Durable Responses to Afatinib as First-line Therapy for HER2-mutated Metastatic Non-small-cell Lung Cancer.

K. Kelly, Tianhong Li, Ebaa Al-obeidi, 2020, Clinical lung cancer.

The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study

S. Schokrpur, K. Kelly, M. Daly, 2022, JTO clinical and research reports.

Response to H. Nabi et al.

K. Kelly, K. Albain, C. Ambrosone, 2018, Journal of the National Cancer Institute.

Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A randomized phase II selectional trial SWOG 0342.

J. Crowley, R. Herbst, K. Kelly, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Irinotecan in small-cell lung cancer: current data.

K. Kelly, Karen Kelly, 2001, Clinical lung cancer.

Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN)

Parth D. Shah, D. Patrick, R. Herbst, 2021, JCO oncology practice.

Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC

J. Bradley, K. Kelly, S. Ramalingam, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.

C. Gridelli, K. Kelly, F. Shepherd, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.

K. Kelly, P. Bunn, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

David Cella, Karen Kelly, Roy S Herbst, 2003, JAMA.

Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.

Lihong Qi, Patrick A Kupelian, Pin-Chieh Wang, 2017, The Lancet. Oncology.

Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non–Small‐cell Lung Cancer: SWOG S0635 and S0636 Trials

F. Hirsch, K. Kelly, A. Wozniak, 2018, Clinical lung cancer.

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

D. Yankelevitz, I. Wistuba, R. Herbst, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study

Edward S. Kim, K. Kelly, L. Paz-Ares, 2018, Clinical Cancer Research.

Brief Report: SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study).

R. Herbst, K. Kelly, D. Gandara, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.

J. Nemunaitis, R. Heist, K. Kelly, 2016 .

SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study).

R. Herbst, K. Kelly, D. Gandara, 2020, Clinical lung cancer.

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.

K. Kelly, J. Edenfield, A. Heydebreck, 2017, The Lancet. Oncology.

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

A. Ravaud, K. Kelly, T. Stinchcombe, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors

K. Kelly, D. Gandara, J. Bomalaski, 2015, Clinical Cancer Research.

Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216).

R. Govindan, S. Mandrekar, S. Hillman, 2022, JAMA oncology.

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

R. Heist, K. Kelly, E. Vokes, 2021, Clinical Cancer Research.

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer

L. Beckett, J. Riess, K. Kelly, 2021, JCO precision oncology.

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

Chun-Ming Tsai, Lucio Crinò, Karen Kelly, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential N-Glycosylation Patterns in Lung Adenocarcinoma Tissue.

H. Pass, W. Rom, K. Kelly, 2015, Journal of proteome research.

A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors

K. Kelly, P. Bunn, A. Baron, 2004, Clinical Cancer Research.

Prophylactic cranial irradiation for patients with small-cell lung cancer.

K. Kelly, P. Bunn, P A Bunn, 1995, Journal of the National Cancer Institute.

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.

L. Schwartz, M. Leblanc, R. Herbst, 2020, The Lancet. Oncology.

OA01.04 Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A

J. Neal, R. Herbst, F. Hirsch, 2021 .

Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review.

K. Kelly, N. Abdel Karim, 2019, The oncologist.

Treatment paradigms in advanced non-small-cell lung cancer.

K. Kelly, C. McCoach, 2013, Clinical advances in hematology & oncology : H&O.

Treatment of Locally Advanced Non-Small Cell Lung Cancer.

K. Kelly, M. Daly, K. Tam, 2017, Hematology/oncology clinics of North America.

Smoking, Sex, and Non–Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424)

W. Bshara, K. Kelly, D. Gandara, 2018, Journal of the National Cancer Institute.

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade

S. Vesely, D. Longo, R. Isseroff, 2018, Nature Medicine.

A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).

L. Schwartz, R. Herbst, F. Hirsch, 2020, Clinical lung cancer.

Phase I study of INC280 plus erlotinib in patients with MET expressing adenocarcinoma of the lung.

L. Beckett, J. Riess, K. Kelly, 2015 .

O-277 CALGB 9732: Final report of a randomized phase III intergroup trial of etoposide(VP-16) and cisplatin (DDP) with or without paclitaxel(TAX) and G-CSF in patients with extensive stage small cell lung cancer(ED-SCLC)

Michael R. Green, R. Marks, K. Kelly, 2003 .

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.

R. Herbst, F. Hirsch, K. Kelly, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

J. Crowley, J. Jett, K. Kelly, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study.

K. Kelly, L. Nadauld, J. Grilley-Olson, 2019, JCO precision oncology.

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC

G. Giaccone, J. Gregg, P. Stephens, 2018, PloS one.

Phase II Study of Gemcitabine and Cisplatin in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group Study 9718

J. Crowley, K. Kelly, V. Israel, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II Trial of Paclitaxel, Carboplatin, and Topotecan with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group 9914

J. Crowley, K. Kelly, G. Weiss, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial

K. Kelly, A. Heydebreck, J. Grewal, 2019, JAMA oncology.

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

G. Rosner, K. Kelly, M. Carducci, 2020, Clinical Cancer Research.

A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results.

Chun-Ming Tsai, Lucio Crino, Shaf Keshavjee, 2014 .

Survival benefits associated with surgery for advanced non–small cell lung cancer

Stina W. Andersen, L. Beckett, K. Kelly, 2019, The Journal of thoracic and cardiovascular surgery.

The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer.

K. Kelly, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Preclinical Evaluation of MET Inhibitor INC‐280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small‐Cell Lung Cancer

K. Kelly, D. Gandara, P. Mack, 2017, Clinical lung cancer.

50 Years of progress in the systemic therapy of non-small cell lung cancer.

H. Wakelee, K. Kelly, M. Edelman, 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Years of Progress in the Systemic Therapy of Non – Small Cell Lung Cancer

H. Wakelee, K. Kelly, M. Edelman, 2014 .

Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced-Stage Non-Small Cell Lung Cancer

C. Obasaju, D. Ettinger, K. Kelly, 2004, Clinical Cancer Research.

The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.

N. Hanna, K. Kelly, P. Bunn, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806)

K. Kelly, G. Weiss, D. Gandara, 2004, Clinical Cancer Research.

Randomized Phase II Trial of Sequential Chemotherapy in Advanced Non-Small Cell Lung Cancer (SWOG 9806): Carboplatin/Gemcitabine followed by Paclitaxel or Cisplatin/Vinorelbine followed by Docetaxel

K. Kelly, G. Weiss, D. Gandara, 2004 .

A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.

K. Kelly, P. Bunn, D. Huffman, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811).

S. Gettinger, K. Kelly, D. Gandara, 2021, Clinical lung cancer.

Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study.

J. Crowley, K. Kelly, P. Bunn, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction

Helen X. Chen, K. Kelly, A. Razak, 2022, Journal of Experimental & Clinical Cancer Research.

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

R. Heist, K. Kelly, E. Vokes, 2021, JTO clinical and research reports.

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors

A. Tolcher, K. Kelly, M. Khasraw, 2021, Journal for ImmunoTherapy of Cancer.

Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.

L. Schwartz, R. Herbst, F. Hirsch, 2021, Clinical Lung Cancer.

Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.

R. Herbst, S. Gettinger, K. Kelly, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CT Volumetry and Basic Texture Analysis as Surrogate Markers in Advanced Non-small-cell Lung Cancer.

K. Kelly, D. Gandara, F. Knollmann, 2019, Clinical lung cancer.

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.

J. Nemunaitis, R. Heist, K. Kelly, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.

K. Kelly, D. Gandara, J. Moon, 2016, Clinical lung cancer.

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.

Mary W Redman, Karen Kelly, J. Crowley, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications.

J. Riess, K. Kelly, D. Gandara, 2014, Clinical lung cancer.

Integration of targeted therapy in the management of locally advanced, unresectable non-small-cell lung cancer

K. Kelly, P. Mack, M. Daly, 2013 .

Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.

J. Crowley, K. Kelly, P. Bunn, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.

K. Kelly, C. Huang, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort

K. Kelly, E. Felip, N. Isambert, 2021, Targeted Oncology.

First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.

K. Kelly, Melissa L. Johnson, Huanyu Chen, 2019, Journal of Clinical Oncology.

First‐line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non–Small‐cell Lung Cancer With Different Prognostic Significance

K. Kelly, R. Camidge, R. Doebele, 2018, Clinical lung cancer.

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer

K. Kelly, D. Gandara, F. Shepherd, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

949 First-in-human study of the first acid pH-sensitive and recycling CTLA-4 antibody that preserves the immune tolerance checkpoint to avoid immunotherapy-related adverse events in cancer patients

K. Kelly, Yang Liu, P. Zheng, 2021, Journal for ImmunoTherapy of Cancer.

Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)

R. Govindan, J. Bradley, S. Mandrekar, 2021, Immunotherapy.

N-Glycan profiling of dried blood spots.

Karen Kelly, L Renee Ruhaak, L. R. Ruhaak, 2012, Analytical chemistry.

EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC.

R. Herbst, F. Hirsch, K. Kelly, 2021, Clinical lung cancer.

Effects of imputation on correlation: implications for analysis of mass spectrometry data from multiple biological matrices

Kyoungmi Kim, Robert H. Weiss, Karen Kelly, 2016, Briefings Bioinform..

P-460 Results of a phase 2 trial of HGS-ETR1 (agonistic humanmonoclonal antibody to TRAIL receptor 1) in subjects with relapsedlrecurrent non-small cell lung cancer (NSCLC)

K. Kelly, J. Crawford, Y. Oh, 2005 .

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.

K. Kelly, J. Crawford, Y. Oh, 2008, Lung cancer.

Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

R. Marks, K. Kelly, J. Herndon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The promise of stereotactic body radiation therapy in a new era of oncology.

K. Kelly, B. Kavanagh, M. Kane, 2007, Frontiers of radiation therapy and oncology.

J. Bradley, K. Kelly, S. Ramalingam, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.

H. Cohen, M. Socinski, R. Govindan, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The inherited nature of lung cancer: a pilot study.

K. Kelly, P. Bunn, M. Wood, 2000, Lung cancer.

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.

N. Hanna, K. Kelly, P. Bunn, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated None—Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure

K. Kelly, D. Barbie, J. Kawashima, 2018, Clinical lung cancer.

Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?

K. Kelly, P. Bunn, 1998, Lung cancer.

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

P. Iyengar, B. Loo, A. Chiang, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.

C. Obasaju, P. Jänne, K. Kelly, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prognostic model for advanced stage nonsmall cell lung cancer

J. Jett, S. Mandrekar, S. Hillman, 2006, Cancer.

A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.

K. Kelly, P. Bunn, M. Wood, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Docetaxel and Exisulind in Previously Treated Non-small Cell Lung Cancer (NSCLC) Patients: A Multicenter, Phase II Clinical Trial

K. Kelly, P. Bunn, E. Vokes, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers

Y. Miller, J. Minna, P. Massion, 2011, Cancer Prevention Research.

A Randomized Phase II Chemoprevention Trial of 13-CIS Retinoic Acid with Or without α Tocopherol or Observation in Subjects at High Risk for Lung Cancer

Y. Miller, F. Hirsch, K. Kelly, 2009, Cancer Prevention Research.

Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.

J. Crowley, K. Kelly, C. Presant, 2002, Journal of the National Cancer Institute.

Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.

R. Heist, K. Kelly, E. Vokes, 2019, Journal of Clinical Oncology.

Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy.

F. Hirsch, K. Kelly, A. Wozniak, 2013, Clinical lung cancer.

Clinical prognostic model for older patients with advanced non-small cell lung cancer.

H. Cohen, J. Bradley, K. Kelly, 2019, Journal of geriatric oncology.

A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533.

K. Kelly, A. Wozniak, D. Gandara, 2015, Clinical lung cancer.

The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non–Small Cell Lung Cancer

K. Kelly, J. Melnikow, R. Canter, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparison of Platinum-Based Chemotherapy in Patients Older and Younger than 70 Years: An Analysis of Southwest Oncology Group Trials 9308 and 9509

K. Kelly, A. Wozniak, D. Gandara, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.

J. Riess, K. Kelly, D. Gandara, 2017, Lung cancer.

Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis.

K. Kelly, D. Gandara, L. Qi, 2014, Lung cancer.

LCMC LEADER neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early-stage lung cancers.

M. Kris, V. Rusch, J. Minna, 2022, Journal of Clinical Oncology.

Neoadjuvant and adjuvant capmatinib in resectable non–small cell lung cancer with MET exon 14 skipping mutation or high MET amplification: GEOMETRY-N trial.

K. Kelly, M. Awad, Jay M. Lee, 2022, Journal of Clinical Oncology.

ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

P. Jänne, R. Govindan, S. Mandrekar, 2020 .

A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors

S. Groshen, K. Kelly, D. Gandara, 2018, Cancer Chemotherapy and Pharmacology.

Predictors of Survival in Small Cell Lung Cancer (SCLC) Patients (pts) < 50 Years of Age: Results from the California Cancer Registry (CCR) - eScholarship

J. Riess, K. Kelly, D. Gandara, 2015 .

Avelumab (anti–PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial.

C. Redfern, K. Kelly, W. Edenfield, 2018 .

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib

M. Socinski, K. Kelly, D. Gandara, 2015, Clinical Cancer Research.

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Susanne M Arnold, Mary W Redman, Karen Kelly, 2018, The Lancet. Oncology.

Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403).

R. Herbst, F. Hirsch, K. Kelly, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.

A. Ravaud, K. Kelly, T. Stinchcombe, 2016 .

Beyond monotherapy: Integrating immunotherapy into current treatment regimens

K. Kelly, 2016 .

Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.

Edward S. Kim, J. Crowley, R. Herbst, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway–Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

R. Herbst, J. Bradley, K. Kelly, 2019, Journal of Thoracic Oncology.

Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small-Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of Southwest Oncology Group Trials

K. Kelly, D. Gandara, J. Moon, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Relevance of platinum sensitivity status in relapsed/refractory extensive stage small cell lung cancer (ES-SCLC) in the modern era: A patient level analysis of SWOG trials

K. Kelly, D. Gandara, J. Moon, 2015 .

SWOG 0802: A randomized phase II trial of weekly topotecan with and without AVE0005 (aflibercept) in patients with platinum-treated extensive-stage small cell lung cancer (E-SCLC).

K. Kelly, D. Gandara, J. Moon, 2012 .

Current role of irinotecan in the treatment of non-small-cell lung cancer.

K. Kelly, 2002, Oncology.

OA03.03 JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC

C. Redfern, K. Kelly, C. Verschraegen, 2017 .

Large-scale screening of ALK fusion oncogene transcripts in archival NSCLC tumor specimens using multiplexed RT-PCR assays.

K. Kelly, D. Gandara, K. Danenberg, 2011, Journal of Clinical Oncology.

The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study.

S. Schokrpur, K. Kelly, M. Daly, 2021, Journal of Clinical Oncology.

Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.

K. Kelly, D. Gandara, J. Moon, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway – Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)

R. Herbst, J. Bradley, K. Kelly, 2019 .

Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung Cancer: SWOG S0536

Edward S. Kim, R. Herbst, F. Hirsch, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy

C. Azzoli, K. Kelly, J. R. Pereira, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Novel approaches for the treatment of small cell lung cancer.

H. Wakelee, K. Kelly, 2004, Hematology/oncology clinics of North America.

83OA phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A

R. Herbst, K. Kelly, D. Gandara, 2017 .

Antigens in lung cancer: clinical radio- immunolocalization in lung cancer

K. Kelly, P. Bunn, 1993 .

Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer.

K. Kelly, P. Bunn, G. Weiss, 2007, Clinical Lung Cancer.

Guidelines for the Evaluation of Pulmonary Nodules Detected Incidentally or by Screening: A Survey of Radiologist Awareness, Agreement, and Adherence From the Watch the Spot Trial.

D. Aberle, D. Miglioretti, K. Kelly, 2020, Journal of the American College of Radiology : JACR.

Methods for the Watch the Spot Trial: A Pragmatic Trial of More vs. Less Intensive Strategies for Active Surveillance of Small Pulmonary Nodules.

D. Miglioretti, K. Kelly, M. Gould, 2019, Annals of the American Thoracic Society.

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer.

J. Riess, K. Kelly, D. Gandara, 2017, Clinical lung cancer.

The benefits of achieving stable disease in advanced lung cancer.

K. Kelly, 2003, Oncology.

Biological Markers for Non–Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

F. Hirsch, K. Kelly, P. Bunn, 2006, Clinical Cancer Research.

Alternative measures predicting clinical benefit in advanced non-small cell lung cancer (NSCLC) from Southwest Oncology Group (SWOG) randomized trials: Implications for clinical trial design.

J. Crowley, K. Kelly, D. Gandara, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity.

L. Beckett, K. Kelly, D. Gandara, 2012, Clinical lung cancer.

OA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D

M. Socinski, J. Engelman, R. Herbst, 2017 .

Early Stage Lung Cancer—New Approaches to Evaluation and Treatment: Conference Summary Statement

C. Henschke, J. Jett, G. Scagliotti, 2005, Clinical Cancer Research.

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

A phase I study of exisulind in previously treated patients with lung cancer

K. Kelly, P. Bunn, N. Mikhaeel, 2000 .

Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non–small cell lung cancer

P. Wen, L. Deangelis, R. Govindan, 2015, Cancer.

Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer.

Oliver Fiehn, Kyoungmi Kim, Harvey I. Pass, 2016, Cancer biomarkers : section A of Disease markers.

Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status.

K. Kelly, 2004, Seminars in oncology.

Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma

K. Kelly, A. Lassman, K. Papadopoulos, 2022, Neuro-oncology advances.

A Phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer

P. Sunpaweravong, K. Kelly, P. Bunn, 2006, Investigational New Drugs.

Genomic mutation profiling (GMP) and clinical outcome in patients (pts) treated with ribociclib (CDK4/6 inhibitor) in the Signature program.

K. Kelly, L. Nadauld, J. Grilley-Olson, 2016 .

Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial.

N. Altorki, K. Kelly, E. Cho, 2014 .

Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site.

K. Kelly, R. Valicenti, S. Stewart, 2018, International Journal of Radiation Oncology, Biology, Physics.

Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC): Preliminary results.

K. Kelly, F. Fossella, J. Schiller, 2004, Journal of Clinical Oncology.

Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy.

J. Crowley, R. Herbst, K. Kelly, 2005, Clinical lung cancer.

Combined Modality Treatment for Locally Advanced Nonsmall-Cell Lung Cancer

K. Kelly, 1996 .

A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients.

Stina W. Andersen, L. Beckett, K. Kelly, 2017, The Annals of thoracic surgery.

Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer.

G. Piazza, K. Kelly, P. Bunn, 2002, Seminars in oncology.

SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).

K. Kelly, L. Byers, C. Gay, 2023, Journal of Clinical Oncology.

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

N. Altorki, K. Kelly, E. Cho, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study.

R. Herbst, F. Hirsch, K. Kelly, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

3090 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or recurrent non-small-cell lung cancer progressing after platinum-based chemotherapy: A phase Ib trial

K. Kelly, A. Heydebreck, W. Edenfield, 2015 .

Avelumab (MSB0010718C ; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial : safety, clinical activity, and PD-L1 expression

C. Redfern, K. Kelly, A. Heydebreck, 2016 .

Phase I study of cisplatin, etoposide, and paclitaxel in patients with extensive-stage small cell lung cancer: a University of Colorado Cancer Center study.

K. Kelly, P. Bunn, 1996, Seminars in Oncology.

K. Kelly, J. Gulley, 2017, Translational cancer research.

Common and rare EGFR mutations (EGFRm) in the RADIANT trial: Final follow-up with 5 year data.

N. Altorki, K. Kelly, F. Shepherd, 2015 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy

C. Azzoli, K. Kelly, J. R. Pereira, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.

K. Kelly, D. Gandara, J. Moon, 2016, Clinical lung cancer.

Increasing Rates of No Treatment in Advanced‐Stage Non–Small Cell Lung Cancer Patients: A Propensity‐Matched Analysis

K. Kelly, Chin-Shang Li, M. Daly, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.

Jordan H. Garst, Edward J. Kim, K. Kelly, 2017, The Lancet. Oncology.

Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers

Y. Miller, J. Minna, P. Massion, 2011, Cancer Prevention Research.

Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site.

K. Kelly, R. Valicenti, S. Stewart, 2018, International journal of radiation oncology, biology, physics.

Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib: A California Cancer Consortium Phase II trial (NCI 8698).

M. Socinski, K. Kelly, D. Gandara, 2014 .

MA 02.10 Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC

R. Heist, K. Kelly, D. Camidge, 2017 .

P-615 Phase II trials of gefitinib (‘Iressa’, ZD1839): rapid and durable objective responses in patients with advanced non-small-cell lung cancer (IDEAL 1 and IDEAl 2)

G. Giaccone, M. Kris, M. Fukuoka, 2003 .